This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boffa, J.-J. Articles by Chatziantoniou, C. Search for Related Content PubMed PubMed Citation Articles by Boffa, J.-J. Articles by Chatziantoniou, C. Related Collections Remodeling Endothelium/vascular type/nitric oxide

(Hypertension. 2001;37:490.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Regression of Renal Vascular Fibrosis by Endothelin Receptor Antagonism

Jean-Jacques Boffa; Pierre-Louis Tharaux; Jean-Claude Dussaule; Christos Chatziantoniou

From INSERM U.489, Hôpital Tenon (J.-J.B., P.-L.T., C.C.); and AP-HP, Laboratoire de Physiologie, Faculté de Médecine St Antoine (J.-C.D.), Paris, France.

Correspondence to Christos Chatziantoniou, INSERM U.489, Hôpital Tenon, Paris 75020, France. E-mail christos.chatziantoniou{at}tnn.ap-hop-paris.fr

In previous studies, we have observed that endothelin participates in the progression of renal vascular and glomerular fibrosis during hypertension by activating collagen I gene synthesis. The present study investigated whether administration of endothelin receptor antagonists leads to the regression of renal sclerotic lesions. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-2 chain promoter. Hypertension was induced by long-term inhibition of nitric oxide synthesis by N^G-nitro-L-arginine methyl ester (L-NAME); systolic pressure gradually increased, reaching a plateau of 165 mm Hg after 10 weeks of hypertensive treatment. At the same time, collagen I gene expression was increased 2- and 5-fold compared with control animals in afferent arterioles and glomeruli, respectively (P<0.01). This increase was accompanied by the appearance of sclerotic lesions within the renal vasculature. When renal vascular lesions had been established (20 weeks of L-NAME), animals were divided into 2 subgroups: the one continued to receive L-NAME, whereas in the other, bosentan, a dual endothelin antagonist, was coadministered with L-NAME for an additional period of 10 weeks. Bosentan coadministration did not alter the increased systolic pressure at 30 weeks; in contrast, collagen I gene activity returned almost to control levels in renal vessels and glomeruli. In this subgroup of animals, renal vascular lesions (collagen and/or extracellular matrix deposition) and mortality rates were substantially reduced compared with untreated mice. These data indicate that endothelin participates in the mechanism(s) of renal vascular fibrosis by activating collagen I gene. Treatment with an endothelin antagonist normalizes expression of collagen I gene and leads to the regression of renal vascular fibrosis and to the improvement of survival, thus providing a complementary curative approach against renal fibrotic complications associated with hypertension.

Key Words: hypertension, essential • nephrosclerosis • collagen • extracellular matrix • endothelin

This article has been cited by other articles:

				C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J., August 2, 2008; 29(16): 1936 - 1948. [Abstract] [Full Text] [PDF]

				M. Flamant, S. Placier, A. Rodenas, C. A. Curat, W. F. Vogel, C. Chatziantoniou, and J.-C. Dussaule Discoidin Domain Receptor 1 Null Mice Are Protected against Hypertension-Induced Renal Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3374 - 3381. [Abstract] [Full Text] [PDF]

				S. Placier, J.-J. Boffa, J.-C. Dussaule, and C. Chatziantoniou Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice Nephrol. Dial. Transplant., April 1, 2006; 21(4): 881 - 888. [Abstract] [Full Text] [PDF]

				N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF]

				C. Chatziantoniou and J.-C. Dussaule Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol, August 1, 2005; 289(2): F227 - F234. [Abstract] [Full Text] [PDF]

				R. Mishra, P. Leahy, and M. S. Simonson Gene expression profile of endothelin-1-induced growth in glomerular mesangial cells Am J Physiol Cell Physiol, November 1, 2003; 285(5): C1109 - C1115. [Abstract] [Full Text] [PDF]

				A. Sorokin and D. E. Kohan Physiology and pathology of endothelin-1 in renal mesangium Am J Physiol Renal Physiol, October 1, 2003; 285(4): F579 - F589. [Abstract] [Full Text] [PDF]

				H. T. Yu Progression of Chronic Renal Failure Arch Intern Med, June 23, 2003; 163(12): 1417 - 1429. [Abstract] [Full Text] [PDF]

				A. V Agapitov and W. G Haynes Role of endothelin in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 1 - 15. [Abstract] [PDF]

				S.-S. Ding, C. Qiu, P. Hess, J.-F. Xi, J.-P. Clozel, and M. Clozel Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure Cardiovasc Res, March 1, 2002; 53(4): 963 - 970. [Abstract] [Full Text] [PDF]